I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...
GlobalData on MSN
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...
The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...
Stocktwits on MSN
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug
AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement ...
The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...
AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of a supplemental new drug application that updates ...
MedPage Today on MSN
FDA Tweaks JAK Inhibitor Indication in Inflammatory Bowel Disease
The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback